Navigation Links
Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana
Date:9/22/2011

HACKENSACK, N.J., Sept. 22, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that it has awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at the University of Pennsylvania and Pennsylvania Muscle Institute an End Duchenne Grant for $98,000.

(Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO)

Dr. Khurana is a molecular geneticist / physiologist and highly accomplished scientist who discovered the utrophin protein (originally named Dystrophin-related protein). This bridge funding will allow Dr. Khurana the resources to continue work to upregulate utrophin and correct the underlying defect in mdx muscle with the objective of translation to the clinic.

Duchenne muscular dystrophy occurs when the dystrophin protein is missing or not functioning. Utrophin is a kind of molecular cousin to dystrophin that can compensate for the lack of dystrophin when it is present in larger than normal quantities.

The End Duchenne Grant Award Program was created by PPMD in partnership with the National Institutes of Health (NIH) in an effort to ensure continuation of promising Duchenne research and translation to human studies. The End Duchenne Grant Award Program is a bridge grant provided by PPMD to selected research projects that receive scores beyond the current funding paylines of the N
'/>"/>

SOURCE Parent Project Muscular Dystrophy
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. USC researchers print dense lattice of transparent nanotube transistors on flexible base
2. Gender-Selection Technique Embraced for Hopeful Parents
3. First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.
4. NIST scientists address wrinkles in transparent film development
5. Scientists produce transparent, light-harvesting material
6. Transparent conductive material could lead to power-generating windows
7. Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space
8. UV-transparent coating for image sensors
9. Parents Guide to Cord Blood Foundation Launches Nations First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood
10. Poplar Healthcare Forms Parent Company, Launches New Web Site
11. enLiven Yogurt Sponsors "Back to School Grocery Giveaway" to Keep Parents and Kids Eating Healthy Foods this Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... , July 27, 2015 Research presented at ... will expand on the studies that led to a ... diagnostic for this disease to receive approval from the ... to breaking Ebola,s grip on West Africa ... and enabling healthcare workers to isolate and treat these ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... combats an,alarming rise in chronic diseases, the Pharmaceutical ... new report on the next,generation of medicines in ... The report found that America,s pharmaceutical research ... - are,testing a record 633 new biotech medicines., ...
... and CHICAGO, Sept. 24 Omeros Corporation, a,Seattle-based ... million debt facility with BlueCrest Capital Finance. The ... by Omeros at closing and the,right, subject to ... $15,million. Other terms were not disclosed., "This ...
... specialty biopharmaceutical company,announces that at its Annual General Meeting today, all resolutions,contained in the notice of meeting ... ... Against Withheld** 1. To ... Emmens as a Director ...
Cached Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Omeros and BlueCrest Announce $20 Million Debt Facility 2Results of the Annual General Meeting Held on September 24, 2008 2Results of the Annual General Meeting Held on September 24, 2008 3
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... powerful class of antioxidants could one day be a potent ... antioxidants called synthetic triterpenoids blocked development of Parkinson,s in an ... days, said Dr. Bobby Thomas, neuroscientist at the Medical College ... of the study in the journal Antioxidants & Redox ...
... Award for Innovative Excellence, the Society,s highest award. ... Fulwyler, the inventor of the electrostatic cell sorter, and ... Dr. Terstappen received his Ph.D. in Applied Physics from ... pioneering cytometry research at Becton Dickinson. In 1994, ...
... July 23, 2012 Scientists at Joslin Diabetes ... (GLP-1), a gut hormone, protects against kidney disease, and ... findings, which are reported today online by Diabetes, may ... harness the actions of GLP-1 to prevent the harmful ...
Cached Biology News:Powerful class of antioxidants may be potent Parkinson's treatment 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 3Joslin researchers gain new understanding of diabetes and kidney disease 2Joslin researchers gain new understanding of diabetes and kidney disease 3
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: